IDH.L Regulatory News (IDH)

24 November 2014

Immunodiagnostic Systems Holdings PLC ("IDS" or "the Group")

Patrik Dahlen Resigns as CEO

Immunodiagnostic Systems Holdings PLC today announces Patrik Dahlen, Chief Executive Officer, has given notice of his resignation from the Company for professional reasons. Patrik will remain in post for a period of up to one year or as may be otherwise agreed. 

Dr Anthony Martin, Non-Executive Chairman, IDS commented:

"On behalf of the Board I would like to thank Patrik sincerely for the contribution he has made to the Company."

Interim results for the six months ending 30 September 2014 will be released as scheduled at 7am GMT on Tuesday 25 November 2014.

For further information:

About Immunodiagnostic Systems Holdings PLC

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.